Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY-3505 in advanced LTK fusion-positive solid tumors
NCT06037317Phase 1Recruiting
- Sponsor
- Shouyao Holdings
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ficonalkib in solid tumor, sponsored by Shouyao Holdings. Primary endpoints: Incidence of adverse events up to 2 years and Incidence of dose limiting toxicities at 28 days. Started May 2024; status: recruiting.
02
Drugs
ficonalkib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06037317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06037317.